- Conference Article
- 10.1136/jitc-2026-itoc.29
P02.15 Optimizing lentiviral vector design and production for cell and gene therapies
- Mar 01, 2026
- Poster presentations
- B Sadler + 7 more +7
ConclusionWhile clinical data indicate that combining TIL-ACT with ANV419 is feasible and potentially better tolerated than conventional HD IL-2, translational data provide evidence for distinct immunological effects of ANV419 compared with LD or HD IL-2 regimens.Together, these findings support the further investigation of IL-2R/-selective IL-2 variants as a strategy to enhance the therapeutic index of TIL therapy.P02.
Read more